retatrutide triple agonist glp-1 gip glucagon receptor The TRIUMPH-1 Phase 3 results just dropped on retatrutide. Here is what the numbers actually say. is a agonist. It targets GLP-1, GIP, and receptors. Ozempic targets one. Mounjaro Targeting GLP-1, GIP & GCG

Now, Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes

I was spending $350/month on diabetes medications, blood pressure pills, and cholesterol drugs, says Robert, a Blissful Wellness patient who lost 68 pounds

Dual agonism with GLP-1 and amylin As WL with GLP-1 RA and amylin analogues results both from distinct and overlapping pathways, a combination of these entero-pancreatic hormones may induce a synergistic WL effect [84]

Researchers combining retatrutide with recovery peptides should be especially attentive to nutritional adequacy and may benefit from stacking protocols that account for timing and injection scheduling